Associate Editor Fauze Maluf-Filho, MD, PhD, FASGE, highlights this Original Article from the September issue: “Survival and clinical outcome after endoscopic duodenal stent placement for malignant gastric outlet obstruction: comparison of pancreatic cancer and nonpancreatic cancer.”

The literature supports the concept that patients with malignant gastric outlet obstruction with a predicted survival longer than 3 months should benefit from surgical bypass. This article challenges this concept. The authors showed a 6 month clinical success rate of 65% for stenting of both patients with pancreatic cancer and nonpancreatic cancer. This article offers a new insight for the endoscopic management of malignant gastric outlet obstruction (GOO).

Clinical outcomes and survival following duodenal stent placement are similar, regardless of the type of cancer (pancreatic vs. nonpancreatic cancer). GOO is a marker for poor survival in either pancreatic or nonpancreatic malignancy. In a well selected population, duodenal stenting may be a viable option for the treatment of patients with malignant gastric outlet obstruction with a predicted survival longer than 3 months.

Find the article abstract here.

The information presented in Endoscopedia reflects the opinions of the authors and does not represent the position of the American Society for Gastrointestinal Endoscopy (ASGE). ASGE expressly disclaims any warranties or guarantees, expressed or implied, and is not liable for damages of any kind in connection with the material, information, or procedures set forth.